Luczynska C, Tredwell E, Smeeton N, Burney P
Department of Public Health Sciences, King's College London, UK.
Clin Exp Allergy. 2003 Dec;33(12):1648-53. doi: 10.1111/j.1365-2222.2003.01729.x.
Mite-allergic patients with allergic disease should benefit from avoiding mite allergens. Many physicians, however, are yet to be convinced that allergen avoidance can make a significant contribution to asthma management in these patients. Many allergen-avoidance regimes include multiple measures of allergen reduction, but as mite exposure in the home is most likely to be greatest in bed dust, bedding is usually the first target for intervention.
This study selected adult patients considered to be most likely to benefit from avoiding mite allergens, namely diagnosed asthmatics, sensitized to house dust mites and exposed to mite allergen in their mattresses. Patients were randomized into a placebo-controlled trial of the use of allergen-impermeable bed covers for 12 months, without any other form of mite-reduction measures.
Adults with asthma were selected from general practices and asthma clinics in south-east London. Their serum IgE to mite allergens and allergen content of mattress dust samples were measured. Those with >0.70 kU/L mite-specific IgE and >2 microg/g Der p 1 were randomized into active or placebo treatments. Information was collected on allergic symptoms and medication use and quarterly peak flow diaries were kept throughout the trial. Dog or cat allergic patients were excluded if they had a pet at home to which they were sensitized.
The mean decrease in microg/g Der p 1 was 25.7 (95% CI 8.9, 74.1) in the active group and 4.5 (95% CI 1.8, 11.5) in the placebo group. Der p 1 concentrations in the active and placebo groups at the end of the trial were not significantly different. There was no effect on peak flow or asthma symptoms in a simple comparison of the treatment and placebo groups.
In this group of patients, mite allergen avoidance in the bed by the use of allergen-impermeable bedding alone cannot be recommended as an effective way of relieving asthma symptoms.
患有过敏性疾病的螨过敏患者应能从避免接触螨过敏原中获益。然而,许多医生仍不相信避免过敏原能对这些患者的哮喘管理做出重大贡献。许多避免过敏原的方案包括多种减少过敏原的措施,但由于家中接触螨最有可能在床尘中最为严重,因此床上用品通常是干预的首要目标。
本研究选择了被认为最有可能从避免螨过敏原中获益的成年患者,即已确诊的哮喘患者,他们对屋尘螨过敏且床垫中接触螨过敏原。患者被随机分为一项为期12个月使用防过敏原床罩的安慰剂对照试验,不采取任何其他形式的减少螨措施。
从伦敦东南部的普通诊所和哮喘诊所选取成年哮喘患者。测量他们对螨过敏原的血清IgE以及床垫灰尘样本中的过敏原含量。螨特异性IgE>0.70 kU/L且Der p 1>2μg/g的患者被随机分为活性治疗组或安慰剂治疗组。收集有关过敏症状和药物使用的信息,并在整个试验期间每季度记录一次峰值流量日记。如果对狗或猫过敏的患者家中有他们致敏的宠物,则将其排除。
活性组中Der p 1的微克/克平均下降量为25.7(95%置信区间8.9,74.1),安慰剂组为4.5(95%置信区间1.8,11.5)。试验结束时活性组和安慰剂组的Der p 1浓度无显著差异。在治疗组和安慰剂组的简单比较中,对峰值流量或哮喘症状没有影响。
在这组患者中,仅通过使用防过敏原床上用品来避免床上的螨过敏原,不能被推荐为缓解哮喘症状的有效方法。